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ABSTRACT: Prioritizing missense variants for further ex-
perimental investigation is a key challenge in current se-
quencing studies for exploring complex and Mendelian
diseases. A large number of in silico tools have been em-
ployed for the task of pathogenicity prediction, including
PolyPhen-2, SIFT, FatHMM, MutationTaster-2, Muta-
tionAssessor, Combined Annotation Dependent Deple-
tion, LRT, phyloP, and GERP++, as well as optimized
methods of combining tool scores, such as Condel and
Logit. Due to the wealth of these methods, an important
practical question to answer is which of these tools gener-
alize best, that is, correctly predict the pathogenic charac-
ter of new variants. We here demonstrate in a study of 10
tools on five datasets that such a comparative evaluation
of these tools is hindered by two types of circularity: they
arise due to (1) the same variants or (2) different variants
from the same protein occurring both in the datasets used
for training and for evaluation of these tools, which may
lead to overly optimistic results. We show that compar-
ative evaluations of predictors that do not address these
types of circularity may erroneously conclude that circu-
larity confounded tools are most accurate among all tools,
and may even outperform optimized combinations of tools.
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Introduction
Current high-throughput techniques to investigate the genetic
basis of inherited diseases yield large numbers of potentially
pathogenic sequence alterations [Tennessen et al., 2012; Purcell
et al., 2014]. Conducting further in-depth functional analyses on
these large numbers of candidates is generally impractical. Reliable
strategies that allow investigators to decide which of these variants
to prioritize are therefore imperative. Researchers will often focus
on nonsynonymous single-nucleotide variants (nsSNVs), which are
disproportionately deleterious comparedwith synonymous variants
[Hindorff et al., 2009; Kiezun et al., 2012; MacArthur et al., 2012],
and filter out common variants, which are presumed to be more
likely to be neutral. However, in many cases, tens of thousands of
candidates still remain after this step. Computational tools that can
be used to identify those missense variants most likely to have a
pathogenic effect, that is, most likely to contribute to a disease, are
therefore of high-practical value.
A number of such tools are already available, such as
MutationTaster-2 (MT2) [Schwarz et al., 2014], LRT [Chun and
Fay, 2009], PolyPhen-2 (PP2) [Adzhubei et al., 2010], SIFT [Ng
and Henikoff, 2003], MutationAssessor (MASS) [Reva et al., 2011],
FatHMM weighted (FatHMM-W) and unweighted (FatHMM-U)
[Shihab et al., 2013], Combined Annotation Dependent Deple-
tion (CADD) [Kircher et al., 2014], phyloP [Cooper and Shendure,
2011], and GERP++ [Davydov et al., 2010]. They are widely used for
separating pathogenic variants from neutral variants in sequenc-
ing studies [Leongamornlert et al., 2012; Rudin et al., 2012; Kim
et al., 2013; Thevenon et al., 2014; Weinreb et al., 2014; Zhao et al.,
2015].While these tools are all commonly applied to the problem of
pathogenicity prediction, the original purposes they were designed
for varies (see Table 1). Some measure sequence conservation (phy-
loP [Cooper and Shendure, 2011], GERP++ [Davydov et al., 2010],
and SIFT [Ng andHenikoff, 2003]), others try to assess the impact of
C© 2015 The Authors. ∗∗Human Mutation published by Wiley Periodicals, Inc.
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Table 1. Overview of the Prediction Tools Used in This Study
Tool (abbreviation) Version N AA Purpose, as stated by developers
PolyPhen-2 (PP2) 2.2.2 Yes Yes “Predicts possible impact of an amino acid substitution on the structure
and function of a human protein using straightforward physical and
comparative considerations”a
MutationTaster-2 (MT2) 2 Yes No “Evaluation of the disease-causing potential of DNA sequence
alterations”b
MutationAssessor (MASS) 2 Yes Yes “Predicts the functional impact of amino acid substitutions in proteins,
such as mutations discovered in cancer or missense polymorphisms”c
LRT – Yes No “Identify a subset of deleterious mutations that disrupt highly
conserved amino acids within protein-coding sequences, which are
likely to be unconditionally deleterious”d
SIFT 1.03 Yes Yes “Predicts whether an amino acid substitution affects protein function”e
GERP++ – Yes No “Identifies constrained elements in multiple alignments by quantifying
substitution deficits. These deficits represent substitutions that would
have occurred if the element were neutral DNA, but did not occur
because the element has been under functional constraint. We refer
to these deficits as “rejected substitutions.” Rejected substitutions are
a natural measure of constraint that reflects the strength of past
purifying selection on the element”f
phyloP – Yes No “Compute conservation or acceleration P values based on an alignment
and a model of neutral evolution”g
FatHMM unweighted
(FatHMM-U)
2.2–2.3 No Yes Predicts “functional consequences of both coding variants, that is,
nonsynonymous single-nucleotide variants, and noncoding
variants”h
FatHMM weighted
(FatHMM-W)
2.2–2.3 No Yes Predicts “functional consequences of both coding variants, that is,
nonsynonymous single-nucleotide variants, and noncoding variants”
and its weighting scheme attributes higher tolerance scores to SNVs
in proteins, related proteins, or domains that already include a high
fraction of pathogenic variantsh
Combined Annotation
Dependent Depletion
(CADD)
1.0 Yes No “CADD is a tool for scoring the deleteriousness of single-nucleotide
variants as well as insertion/deletions variants in the human
genome”i
For each tool, the first column shows the version of the tool, the second column (N) shows whether it accepts nucleotide changes as input, the third column (AA) shows whether
it accepts amino acid changes as input. The last column provides a description of the tool, as stated by the developers.
ahttp://genetics.bwh.harvard.edu/pph2/index.shtml
bhttp://www.mutationtaster.org
chttp://mutationassessor.org
dhttp://www.genetics.wustl.edu/jflab/lrt_query.html
ehttp://sift.jcvi.org
fhttp://mendel.stanford.edu/sidowlab/downloads/gerp/index.html
ghttp://compgen.bscb.cornell.edu/phast/
hhttp://fathmm.biocompute.org.uk
ihttp://cadd.gs.washington.edu/home
variants on protein structure or function (e.g., PP2 [Adzhubei et al.,
2010]) or to quantify the overall pathogenic potential of a variant
basedondiverse types of genomic information (e.g.,CADD[Kircher
et al. 2014]). Note that SIFT is both a measure of sequence conser-
vation and provides an analytically derived threshold for predicting
whether or not protein function will be affected [Ng and Henikoff,
2003]. Furthermore, popular benchmark datasets for pathogenicity
prediction differ in the way they define the pathogenic or neutral
character of a variant (see Table 2). For instance, neutral variants
are supposed to have a minor allele frequency larger than 1% in
HumVar [Adzhubei et al., 2010], of less than 1% in ExoVar [Li et al.,
2013], and of more than 40% in VariBench [Thusberg et al., 2011;
Nair and Vihinen, 2013].
Given this wealth of different methods and benchmarks that
can be used for pathogenicity prediction, an important practical
question to answer is whether one or several tools systematically
outperform all others in prediction accuracy. To address this ques-
tion, we comprehensively assess the performance of 10 tools that
are widely used for pathogenicity prediction: MT2 [Schwarz et al.,
2014], LRT [Chun and Fay, 2009], PP2 [Adzhubei et al., 2010], SIFT
[NgandHenikoff, 2003],MASS [Reva et al., 2011], FatHMM-Wand
FatHMM-U [Shihab et al., 2013], CADD [Kircher et al., 2014], phy-
loP [Cooper and Shendure, 2011], and GERP++ [Davydov et al.,
2010]. We evaluate performance across major public databases
previously used to test these tools [Adzhubei et al., 2010; Mottaz
et al., 2010; Thusberg et al., 2011; Li et al., 2013; Nair and Vihi-
nen, 2013; Bendl et al., 2014] and show that two types of circularity
severely affect the interpretation of the results. Here, we use the
term “circularity” to describe the phenomenon that predictors are
evaluated on variants or proteins that were used to train their pre-
diction models. While a number of authors have acknowledged the
existence of one particular form of circularity before (stemming
specifically from overlap between data used to develop the tools
and data upon which those tools are tested) [Adzhubei et al., 2010;
Thusberg et al., 2011; Nair and Vihinen, 2013; Vihinen, 2013], our
study is the first to provide a clear picture of the extent and impact
of this phenomenon in pathogenicity prediction.
The first type of circularity we encounter is due to overlaps be-
tween datasets that were used for training and evaluation of the
models. Tools such as MT2 [Schwarz et al., 2014], PP2 [Adzhubei
et al., 2010], MASS [Reva et al., 2011], and CADD [Kircher et al.,
2014], which require a training dataset to determine the parameters
of the model, run the risk of capturing idiosyncratic characteristics
of their training set, leading to poor generalization when applied
on new data. To prevent the phenomenon of overfitting [Hastie
et al., 2009], it is imperative that tools be evaluated on variants that
were not used for the training of these tools [Vihinen, 2013]. This
is particularly true when evaluating combinations of tool scores, as
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Table 2. Purpose of Each Dataset, as Described by Dataset Creators
Dataset Purpose Positive control: damaging/deleterious/disease
causing/pathogenic
Negative control: neutral/benign/nondamaging/tolerated
HumVar Mendelian disease variant
identification
“All disease-causing mutations from UniProtKB”a “Common human nsSNPs (MAF > 1%) without annotated
involvement in disease . . . treated as nondamaging”a
ExoVar “Dataset composed of pathogenic
nsSNVs and nearly
nonpathogenic rare nsSNVs”b
“5,340 alleles with known effects on the molecular
function causing human Mendelian diseases from the
UniProt database . . . positive control variants.”
“Pathogenic nsSNVs”b
“4,752 rare (alternative/derived allele frequency <1%)
nsSNVs with at least one homozygous genotype for the
alternative/derived allele in the 1000 Genomes
Project . . . negative control variants.” “Other rare
variants”b
VariBench “Variation datasets affecting
protein tolerance”c
“The pathogenic dataset of 19,335 missense mutations
obtained from the PhenCode database downloaded in
June 2009), IDbases and from 18 individual LSDBs.
For this dataset, the variations along with the variant
position mappings to RefSeq protein (> = 99% match),
RefSeq mRNA, and RefSeq genomic sequences are
available for download.”c
“This is the neutral dataset or nonsynonymous coding SNP
dataset comprising 21,170 human nonsynonymous
coding SNPs with allele frequency 40.01 and chromosome
sample count 449 from the dbSNP database build 131.
This dataset was filtered for the disease-associated SNPs.
The variant position mapping for this dataset was
extracted from dbSNP database.”c
predictSNP “Benchmark dataset used for the
evaluation of . . . prediction tools
and training of consensus
classifier PredictSNP”d
Disease-causing and deleterious variants from SwissProt,
HGMD, HumVar, Humsavar, dbSNP, PhenCode,
IDbases, and 16 individual locus-specific databases.
Neutral variants from SwissProt, HGMD, HumVar,
Humsavar, dbSNP, PhenCode, IDbases, and 16 individual
locus-specific databases.
SwissVar “Comprehensive collection of
single amino acid
polymorphisms (SAPs) and
diseases in the
UniProtKB/Swiss-Prot
knowledgebase”e
“A variant is classified as disease when it is found in
patients and disease association is reported in
literature. However, this classification is not a
definitive assessment of pathogenicity”f
“A variant is classified as polymorphism if no disease
association has been reported”f
For each dataset, the first column shows the general purpose. The last two columns describe the positive and negative control categories of variants.
ahttp://genetics.bwh.harvard.edu/pph2/dokuwiki/overview
bhttp://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1003143
chttp://structure.bmc.lu.se/VariBench/tolerance_dataset1.php
dhttp://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1003440
ehttp://bioinformatics.oxfordjournals.org/content/26/6/851.long
fhttp://swissvar.expasy.org/cgi-bin/swissvar/documentation
different tools have been trained on different datasets, increasing the
likelihood that variants in the evaluation set appear in at least one
of these datasets [Gonza´lez-Pe´rez and Lo´pez-Bigas, 2011; Capriotti
et al., 2013; Li et al., 2013; Bendl et al., 2014]. Notably, this type
of circularity, which we refer to as type 1 circularity, could cause
spurious increases in prediction accuracy for both single tools and
combinations of tool scores.
The second type of circularity, which we refer to as type 2 cir-
cularity, is closely linked to a statistical property of current variant
databases: often, all variants from the same gene are jointly labeled
as being pathogenic or neutral. As a consequence, a classifier that
predicts pathogenicity based on known information about specific
variants in the same gene will achieve excellent results, while be-
ing unable to detect novel risk genes, for which no variants have
been annotated before. Further, it will not be able to perform an-
other critical function: discrimination of pathogenic variants from
neutral ones within a given protein.
Furthermore, we evaluate the performance of two tools that com-
bine scores across methods, Condel [Gonza´lez-Pe´rez and Lo´pez-
Bigas, 2011] and Logit [Li et al., 2013], and examine whether
these tools are affected by circularity as well. These tools are based
on the expectation that individual predictors have complementary
strengths, because they rely on diverse types of information, such as
sequence conservation or modifications at the protein level. Com-
bining them hence has the potential to boost their discriminative
power, as reported in a number of studies [Gonza´lez-Pe´rez and
Lo´pez-Bigas, 2011; Capriotti et al., 2013; Li et al., 2013; Bendl et al.,
2014]. The problem of circularity, however, could be exacerbated
when combining several tools. First, consider the case where the
data that are used to learn the weights assigned to each individual
predictor in the combination also overlaps with the training data of
one or more of the tools. Here, tools that have been fitted to the data
already will appear to perform better and may receive artificially
inflated weights. Second, consider the case where the data used to
assess the combination of tools overlaps with the data on which the
tools have been trained. Here, the tools themselves are biased to-
ward performing well on the evaluation data, which can make their
combination appear to perform better than it actually does.
Materials and Methods
Datasets and Data Preprocessing
In this study, we used five different datasets to assess the per-
formance of available prediction tools and their combinations. We
used publicly available and commonly used benchmark datasets:
HumVar [Adzhubei et al., 2010], ExoVar [Li et al., 2013], VariBench
[Thusberg et al., 2011; Nair and Vihinen, 2013], predictSNP [Bendl
et al., 2014], and the latest SwissVar (December 2014) database
[Mottaz et al. 2010] (Table 3). As these tools can require either nu-
cleotide or amino acid substitutions as input, we used Variant Effect
Predictor (VEP) [McLaren et al., 2010] to convert between both for-
mats. We excluded all variants for which we could not determine an
unambiguous nucleotide or amino acid change. Note that by con-
trast, analyses such as that of Thusberg et al. (2011) only assess tools
that require amino acid changes as input. As the intersection of the
trainingdata fromthe toolCADD[Kircher et al., 2014] and thatof all
other datasets is small (fewer than a hundred variants), we systemat-
ically excluded all variants overlappingwith theCADD training data
from all other data sets. TheVariBench dataset (benchmark database
for variations) was created [Thusberg et al., 2011; Nair and Vihi-
nenm 2013] to address the problem of type 1 circularity. However,
while the pathogenic variants of this dataset were new, its neutral
variants may have been present in the training data of other tools.
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Table 3. All Datasets Used in This Study
Datasets Deleterious variants
(D)
Neutral variants (N) Total Ratio (D:Total) Tools potentially
trained on data (fully
or partly)
Removed variants
overlapping with:
HumVar 21,090 19,299 40,389 0.52 MT2, MASS, PP2,
FatHMM-W
CADD training data
ExoVar 5,156 3,694 8,850 0.58 MT2, MASS, PP2,
FatHMM-W
CADD training data
VariBenchSelected 4,309 5,957 10,266 0.42 MT2 CADD training data,
HumVar, ExoVar
predictSNPSelected 10,000 6,098 16,098 0.62 MT2 CADD training data,
HumVar, ExoVar,
VariBench
SwissVarSelected 4,526 8,203 12,729 0.36 MT2 CADD training data,
HumVar, ExoVar,
VariBench, predictSNP
These preprocessed and filtered datasets are used to evaluate the performance of different prediction tools.
VariBench has an overlap of approximately 50% with bothHumVar
and ExoVar (Supp. Fig. S1). We kept the nonoverlapping variants to
build an independent evaluationdataset,whichwecalledVariBench-
Selected and make available along with this manuscript (Supp. Data
S1). From the predictSNP benchmark dataset, we systematically ex-
cludedall variants that overlapwithHumVar,ExoVar, andVariBench
and called the resulting dataset predictSNPSelected. Eventually, we
created a fifth dataset, SwissVarSelected. Here, we excluded from
the latest SwissVar database (December 2014) all variants overlap-
ping with the other four datasets — HumVar, ExoVar, VariBench,
and predictSNP. Thus, SwissVarSelected should be the dataset con-
taining the newest variants across all datasets. With one possible
exception, none of the prediction tools or conservation scores we
investigated in this manuscript were trained on VariBenchSelected,
predictSNPSelected, or SwissVarSelected. The exception is that some
variants in the selected datasets may overlap partially with variants
used to train MT2 [Schwarz et al., 2014] because MT2 was trained
on private data (a large collection of disease variants from HGMD
Professional [Stenson et al., 2014]).
Pathogenicity Prediction Score Sources and Conservation
Scores
For any given variant, we obtained scores and prediction labels for
each tool directly from their respective Web servers or standalone
tools (Table 1). The pathogenicity score of a missense variant may
dependonwhich transcript of the corresponding gene is considered.
For this reason, we standardized our analyses by examining the
same transcript across all tools; if available, we chose the canonical
transcript [Hubbard et al., 2009]. In contrast, ANNOVAR [Wang
et al., 2010] and dbNSFP 2.0 [Liu et al., 2013] use the transcript
that yields the worst (e.g., most damaging) score, which means that
different tools may select different transcripts for the same variant.
Data Availability and Reproducibility of Results
For each dataset, we compiled comma-separated files contain-
ing all obtained tool scores and predicted labels as well as in-
formation about the variant (true label, nucleotide and amino
acid changes, minor allele frequencies, UniProt accession IDs
[Magrane and Consortium, 2011], Ensembl gene, transcript and
protein IDs [Flicek et al. 2014], and dbSNP IDs (rs#) if available
[Sherry et al., 2001]). All these datasets including the tool pre-
dictions can be found at the VariBench Website (http://structure.
bmc.lu.se/VariBench/GrimmDatasets.php) as well as a single Excel
file at the journals Website (Supp. Data S2).
Further, we provide all Python scripts used to generate all tables
and figures in this study along with all datasets, compressed as a
single ZIP file (Supp. Data S1). All data and Python scripts can
also be downloaded from: http://www.bsse.ethz.ch/mlcb/research/
bioinformatics-and-computational-biology/pathogenicity-predi-
ction.html.
Performance Evaluation
To evaluate the performance of all the tools in this study, we used
a collection of statistics derived from a confusion matrix. To this
end, we counted a correctly classified test point as a true positive
(TP) if and only if the test point corresponds to the positive class
(pathogenic or damaging) and as a true negative (TN) if and only
if the test point corresponded to the negative class (neutral or be-
nign). Accordingly, a false positive (FP) is a negative test point that
is classified to be positive and a false negative (FN) a positive test
point classified as a negative one. Since a few datasets are slightly
unbalanced, we assessed the performance of the single tools by com-
puting receiver operating characteristic curves (ROC-curves). Fur-
thermore, we computed Precision-Recall curves (ROC-PR-curves)
[Davis and Goadrich 2006]. The ROC-curve is the fraction of the
TP over all positives TP+FN (sensitivity or TP rate) against the frac-
tion of the FP over all negatives TN+FP (1-specificity or FP rate),
whereas the ROC-PR curve is the fraction of the TP over all positives
TP+FN (recall or sensitivity) against the fraction of the TP over all
TP+FP (precision). To measure the performance, we computed the
area under the ROC and ROC-PR curves (AUC and AUC-PR, re-
spectively). The area under the curve can take values between 0 and
1. A perfect classifier has an AUC and AUC-PR of 1. The AUC of a
random classifier is 0.5. Additionally, we assessed the performance
with seven commonly used parameters as described in the Human
Mutation guidelines [Vihinen, 2012 , 2013] and reported the results
in the Supp. Information:
Accuracy =
TP +TN
TP + FP +TN+ FN
(1)
Precision =
TP
TP + FP
(2)
Recall/Sensitivity =
T P
T P + F N
(3)
Specificity =
TN
FP +TN
(4)
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F –Score = 2
Precision × Recall
Precision +Recall
(5)
Negative Predictive Value (NPV) =
TN
TN + FN
(6)
MatthewsCorrelationCoefficient (MCC)
=
TP × TN – FP × FN√
(TP + FP)(TP + FN)(TN+ FP)(TN+ FN)
(7)
Evaluation of the Weighting Scheme of FatHMM-W
Given the superior performance of FatHMM-W on VariBenchS-
elected and predictSNPSelected (see Results and Fig. 1), we examined
this prediction tool in more detail. This section provides relevant
details about FatHMM’s weighted (FatHMM-W) and unweighted
(FatHMM-U) versions and our evaluation of the weighting of
FatHMM, which accounts for its superior performance. To evaluate
the role of theweighting schemeof FatHMM-W[Shihab et al., 2013]
(Supp. Text S1), we compared the original FatHMM-W method
with an L1-regularized logistic regression [Lee et al., 2006] over
the log-transformed features ln(Wn) and ln(Wd). These features are
used by FatHMM to reweight the FatHMM-U score and construct
FatHMM-W, the weighted version of FatHMM (Supp. Text S1). We
performed a 10-fold cross-validation on the five datasets HumVar
[Adzhubei et al., 2010], ExoVar [Li et al., 2013], VariBenchSelected
[Thusberg et al., 2011; Nair and Vihinen, 2013], predictSNPSelected
[Bendl et al., 2014], and SwissVarSelected [Mottaz et al., 2010] (see
Table 3 and the Methods section). For this purpose, we randomly
split the dataset of interest into 10 subsets of equal size (to the extent
possible). Simultaneously, we kept the ratio of neutral to pathogenic
variants the same across all subsets. This avoids generating a biased
subset containing only variants of the same kind.We then combined
nine subsets to train themodel and used the remaining one to assess
the performance (testing). We repeated this cross-validation proce-
dure 10 times. Because we were using a regularization term, we had
to find a trade-off between the matching model on the training set
and the best generalization. For this purpose, we had to select a rea-
sonable value C. This we did by performing an internal line-search
for each fold to find the Cj that leads to the best AUC from a set of C
values, C = (1e-4, 1e-3, 1e-2, 1e-1, 1, 1e1, 1e2). The overall perfor-
mance of the model was the average across all 10 AUC values. We
then computed AUC, AUC-PR, and the seven commonly used pa-
rameters as described in the Human Mutation guidelines [Vihinen,
2012, 2013]. For our experiments, we used custom Python scripts
(see Supp. Data S1) and scikit-learn [Pedregosa et al., 2011], an
efficient machine learning library for Python that includes an L1-
regularized logistic regression using the LIBLINEAR library [Fan
et al., 2008].
Protein Majority Vote
To analyze how protein-related features can influence the perfor-
mance of the prediction tools, we performed a proteinmajority vote
(MV). For each of the five evaluation datasets, we split the bench-
mark into 10 subsets, and for each of the subsets, used the union
of the nine other subsets as training data. Within that framework,
we scored a variant by the pathogenic-to-neutral ratio, in the train-
ing data, of the protein that variant belongs to. If the protein did
not appear in the training data, we assigned a score of 0.5. This
strategy, while statistically effective on the currently existing
databases, is not appropriate, as it cannot discriminate between
neutral and pathogenic variants within the same protein.
Results
Evaluation of 10 Pathogenicity Prediction Tools on Five
Variant Datasets
We evaluated the performance of eight different prediction tools:
MT2 [Schwarz et al., 2014], LRT [Chun and Fay, 2009], PP2
[Adzhubei et al., 2010], SIFT [Ng andHenikoff, 2003], MASS [Reva
et al., 2011], FatHMM-W and FatHMM-U [Shihab et al., 2013],
and CADD [Kircher et al., 2014] as well as two conservation scores:
phyloP [Cooper and Shendure, 2011] and GERP++ [Davydov et al.,
2010]. An overview of these tools and conservation scores can be
found in Table 1. Details on how these scores were obtained can be
found in the Methods section.
We evaluated these tools using a range of preprocessed public
datasets and subsets of VariBench, predictSNP, and SwissVar (see
Methods), resulting in five evaluation datasets [Adzhubei et al., 2010;
Mottaz et al., 2010; Thusberg et al., 2011; Li et al., 2013; Nair and
Vihinen, 2013; Bendl et al., 2014] (see Methods; Table 3; Supp.
Fig. S1). Importantly, two of these datasets (HumVar [Adzhubei
et al., 2010] and ExoVar [Li et al., 2013]) overlap with at least one
of the training sets used to train the individual tools FatHMM-W,
MT2, MASS, and PP2 (Supp. Fig. S1; Table 3). The selected datasets
canbe considered tobe truly independent evaluationdatasets,which
are free of type 1 circularity (see Methods).
We report AUC values per tool and per dataset in Figure 1 and
Supp. Table S1 (corresponding ROC, PR curves, AUC/AUC-PR
values as well as other evaluation metrics can be found in Supp.
Figs. S2–S6 and Supp. Table S1). Hatched bars in Figure 1 indi-
cate that the evaluation data were used in part or entirely to train
the corresponding tool; these results may suffer from overfitting.
Dotted bars indicate that the tools are biased, due to type 2 circular-
ity (see section “Type 2 Circularity as an Explanation of the Good
Performance of FatHMMWeighted”).
Five central observations can bemade in Figure 1: first, on the two
benchmarksHumVar andExoVar, the fourbest performingmethods
were fully or partly trained on these datasets. Second, while MT2,
PP2, and MASS outperform CADD and SIFT on benchmarks that
include some of their training data (HumVar,ExoVar), this is not the
case on the independent VariBenchSelected and predictSNPSelected
datasets. A potential explanation is that type 1 circularity — that is
overlap between training and evaluation sets—might lead to overly
optimistic results on the first two datasets. Third, across the first four
datasets, FatHMM-W outperforms all other tools (Supp. Table S1;
Fig. 1). All measured evaluation criteria support these findings on
the VariBenchSelected and predictSNPSelected datasets (Supp. Table
S1), even though FatHMM-W has no type 1 bias on VariBenchS-
elected and predictSNPSelected. However, it is confounded by type
2 circularity. Fourth, FatHMM-W shows a severe drop in perfor-
mance on the SwissVarSelected dataset. Finally, we observed across
all datasets that trained predictors generally outperform untrained
conservation scores.
Type 2 Circularity as an Explanation of the Good
Performance of FatHMMWeighted
The superiority of FatHMM-W’s [Shihab et al., 2013] predictions
on VariBenchSelected and predictSNPSelected and the severe drop in
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Figure 1. Evaluation of the 10 different pathogenicity prediction tools (by AUC) over five datasets. The hatched bars indicate potentially biased
results, due to the overlap (or possible overlap) between the evaluation data and the data used (by tool developers) for training the prediction tool.
The dotted bars indicate that the tool is biased due to type 2 circularity. The protein MV predictor and the logistic regression (over the features
used in the weighting scheme of FatHMM-W) are discussed in the second part of the Results section.
performance on SwissVarSelectedmade us investigate its underlying
model to find the reason for its superior performance on all but one
dataset. FatHMM-W’s weighting scheme attributes higher scores to
amino acid substitutions in proteins, related proteins, or domains
that already include a high fraction of pathogenic variants (see Supp.
Text S1). A key element of this weighting scheme is the use of the
two parametersWn andWd, which represent the relative frequency
of neutral variants (Wn) and pathogenic variants (Wd) in the rele-
vant protein family, defined through SUPERFAMILY [Gough et al.,
2001] or Pfam [Sonnhammer et al., 1997]. To further evaluate the
role of this weighting in the performance of FatHMM-W, we com-
pared the original FatHMM-W with a logistic regression over the
features (ln(Wn) and ln(Wd)) in a 10-fold cross-validation on the
selected datasets (see Methods and Supp. Text S1). The use of these
features alone was sufficient to achieve approximately the same
predictive performance as FatHMM-W (see Supp. Table S2 and
Fig. 1).
Given that the ratio of neutral andpathogenic variants in the same
protein family is the key feature used by FatHMM-W, we further
analyzed how an even simpler statistic— the fraction of pathogenic
variants in the same protein — performs as a predictor. We refer
to this predictor as a protein MV (see Methods). MV systematically
outperforms FatHMM-W (Supp. Table S2; Fig. 1). The pathogenic-
ity of neighboring variants within the same protein is therefore the
best predictor of pathogenicity across these datasets. This strategy,
while statistically effective on the currently existing databases, is not
appropriate. Indeed, it assigns the same label to all variants in the
same protein, based on information likely obtained at the protein
level (i.e., that it is associated with a disease), and cannot distin-
guish between pathogenic and neutral variants within the same
protein.
To better understand the outstanding performance of FatHMM-
W and the protein-based MV, we examined the relative frequency
of pathogenic variants across proteins in all our datasets. In the
independent evaluation dataset VariBenchSelected, we found that
more than 98% of all proteins (4,425 out of 4,490; Table 4) contain
variants from a single class, that is, either “pathogenic” or “neu-
tral” (Fig. 2A). For the remainder of the manuscript, we shall refer
to proteins with only one class of variant as “pure” proteins (di-
vided in “pathogenic-only” proteins and “neutral-only” proteins).
The existence of such “pure” proteins — while theoretically pos-
sible — should not be interpreted as a biological phenomenon.
Rather, these designations are based on current knowledge, and
are at least partially an artifact of how these particular datasets are
populated.
Nearly all (94.8%) variants in VariBenchSelected are located in
pure proteins with 57.2% in neutral-only proteins and 37.6% in
pathogenic-only proteins (Fig. 2B). On such a dataset, excellent ac-
curacies can be achieved by predicting the status of a variant based
on the other variants in the same protein. We refer to this phe-
nomenon as type 2 circularity. The remaining 5.2% of VariBench-
Selected variants are located in “mixed” proteins (Fig. 2B and C),
which contain both pathogenic and neutral variants (pathogenic-
to-neutral ratio in the open interval ]0.0, 1.0[ (in Fig. 2C). While
theMV approach will necessarily misclassify some of these variants,
it will still perform well on proteins containing primarily neutral or
primarily pathogenic variants, and overall, only 0.7% of all variants
are in proteins containing an almost balanced ratio of pathogenic
and neutral variants (pathogenic-to-neutral ratio in the interval
[0.4, 0.6] in Fig. 2C). Similar dataset compositions can be observed
in the other three datasetsHumVar, ExoVar, and predictSNPSelected
(Supp. Figs. S7–S9). A striking property of SwissVarSelected is its
much larger fraction of proteins with almost balanced pathogenic-
to-neutral ratio: 6.5% of all variants (832 out of 12,729) can be
found in the most balanced category of mixed proteins [0.4, 0.6]
(see Supp. Fig. S10), compared with an average of 1.5% in the other
four datasets.
To further understand FatHMM-W’s performance, we evaluated
it separately onmixed proteins. As shown in Figure 3, Supp. Figures
S11 and S12, FatHMM-W performs well on pure proteins but loses
much of its predictive power on themixed proteins, as it is misled by
its weighting scheme. On almost-balanced proteins, FatHMM-W is
therefore outperformed by all other tools but phyloP (Fig. 3). This
may also be the first reason why FatHMM-W performs worse on
SwissVarSelected than on all other datasets: SwissVarSelected con-
tains many more variants in the most mixed categories (Fig. S10).
FatHMM-W even performs poorly on mixed proteins from its own
training dataset (Supp. Fig. S11).We observed that PolyPhen-2 out-
performs all other tools in the mixed categories for the datasets
predictSNPSelected and SwissVarSelected (Supp. Fig. S12). For the
VariBenchSelecteddataset, no clearwinner canbedetermined (Supp.
Fig. S12).
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Table 4. Protein Categories and Variants Per Category
Datasets “Pure”
pathogenic
proteins
Pathogenic
variants in
“pure”
proteins
“Pure”
neutral
proteins
Neutral
variants in
“pure”
proteins
Mixed
proteins
Variants in mixed
proteins
Total number of proteins
HumVar 1,277 10,484 8,400 17,140 911 12,765 10,588
ExoVar 891 4,336 2,794 3,478 165 1,036 3,850
VariBenchSelected 286 3,865 4,139 5,869 65 532 4,490
predictSNPSelected 855 7,090 3,738 5,649 228 3,359 4,821
SwissVarSelected 1,444 2,749 3,614 6,568 540 3,412 5,598
Overview about the total number of proteins per dataset and the composition of these datasets.
Figure 2. In the VariBenchSelected dataset, most SNPs are in genes with only neutral or only pathogenic variants. A: Protein perspective:
proportion of proteins containing only neutral variants (“neutral-only”), only pathogenic variants (“pathogenic-only”), and both types of variants
(“mixed”). Only 1.4% of the proteins are mixed. B: Variant perspective: proportions, of variants in each of the three categories of proteins. Only 5.2%
of variants are in mixed proteins. C: Fractions of variants, in the VariBenchSelected dataset, containing various ratios of pathogenic-to-neutral
variants, binned into increasingly narrow bins, approaching balanced proteins. The open interval ]0.0, 1.0[ contains all mixed proteins (as in B).
Only 0.7% of all variants belong to almost perfectly balanced proteins (closed interval [0.4, 0.6]).
The second reason for the drop in performance is the presence
of “new” proteins in SwissVarSelected that are unknown to the
FatHMM-Wweighting database. To show this, we used theHumVar
and ExoVar datasets as a proxy for the training data among all our
tools (FatHMM’s training data is not fully publicly available). We
observed that approximately 91% of all pathogenic and approxi-
mately 68% of all neutral variants in VariBenchSelected are located
in proteins that also occur in HumVar/ExoVar (Supp. Fig. S13 and
Supp. Table S3). As FatHMM-W makes use of information from
protein families, we computed pairwise BLASTP [Camacho et al.,
2009] alignments between all proteins in our selected datasets and
proteins in HumVar/ExoVar. Approximately 99% of all pathogenic
variants in VariBenchSelected are located in proteins from Hum-
Var/Exovar or proteins with more than 70% sequence similarity to
a protein in HumVar/Exovar. Similar statistics can be observed for
predictSNPSelected (Supp. Fig. S13 and Supp. Table S4). However,
for SwissVarSelected, we observed that only approximately 61% of
all pathogenic and approximately 56% of all neutral variants be-
long to proteins from HumVar/ExoVar (Supp. Fig. S13 and Supp.
Table S5). Approximately 78% of all pathogenic and approximately
77% of all neutral variants in SwissVarSelected are located in pro-
teins fromHumVar/ExoVar or in proteins with high-sequence simi-
larity (70% sequence similarity) to a protein from HumVar/ExoVar
(Supp. Fig. S13 and Supp. Table S5). Hence, a significant proportion
of SwissVarSelected variants cannot be found in proteins from the
proxy training dataset or proteins with high-sequence similarity. All
of these findings lead to the conclusion that FatHMM-W’s good
performance on VariBenchSelected and predictSNPSelected is largely
due to type 2 circularity.
Evaluation of Two Combined Predictors
After studying in silico tools for pathogenicity prediction,we com-
pared the performance of two methods that combine individual
tools into a joint prediction, the metapredictors Condel [Gonza´lez-
Pe´rez and Lo´pez-Bigas, 2011] and Logit [Li et al., 2013]. Based on
our previous findings, we were interested in how their performance
compares when evaluated on datasets that avoid type 1 circularity.
Furthermore, we wanted to compare the performance of metapre-
dictors that include FatHMM-W and may suffer from type 2 circu-
larity, to metapredictors that do not include FatHMM-W.
Condel’s Web server provides two combinations of tool scores:
the older (original) version combines PP2 [Adzhubei et al., 2010],
SIFT [Ng and Henikoff, 2003], and MASS [Reva et al., 2011] and
the latest one adds FatHMM-W [Shihab et al., 2013]. We refer to
these two combinations as Condel and Condel+, respectively (Supp.
Table S6). To provide a fair comparison, we used the same sets of
tools for the Logit (and Logit+) model by Li et al. (2013) (Logit
and Logit+, see Supp. Table S6). Thus, in our manuscript, Logit
combines PP2, SIFT, and MASS; Logit+ combines these three tools
and FatHMM-W.
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Figure 3. Performance of 10 pathogenicity prediction tools according to protein pathogenic-to-neutral variant ratio. Evaluation of tool perfor-
mance on subsets of VariBenchSelected, predictSNPSelected, and SwissVarSelected, defined according to the relative proportions of pathogenic
and neutral variants in the proteins they contain. “Pure” indicates variants belonging to proteins containing only one class of variant. (x and y)
indicate variants belonging to mixed proteins, containing a ratio of pathogenic-to-neutral variants between x and y. ]0.0, 1.0[ therefore indicate
all mixed proteins (the ratios of 0.0 and 1.0 being excluded by the reversed brackets). While FatHMM-W performs well or excellently on variants
belonging to pure proteins (VariBenchSelected and predictSNPSelected), it performs poorly on those belonging to mixed proteins.
To avoid type 1 circularity, we chose the selected datasets as our
evaluation datasets, as they do not overlap with the training dataset
of any individual tool or metapredictor. Our results using Logit on
all selected datasets confirm those reported by Li et al. (2013): Logit
outperforms all individual tools andCondel in terms of AUC (Fig. 4;
Supp. Figs. S14–S18). Condel’s performance (AUC = 0.70) is on par
with SIFT (AUC = 0.70) for VariBenchSelected, the best performing
of the tools it combines.We then evaluated the combination of tools
on the pure and mixed proteins on VariBenchSelected, predictSNPS-
elected, and SwissVarSelected (Supp. Fig. S19). While Logit performs
well on the pure proteins, Condel performs at least as well as Logit
on variants in mixed proteins.
The evaluation of Condel+ and Logit+ may be optimistically bi-
ased by type 2 circularity, given the inclusion of FatHMM-W. Across
all datasets, we observed that adding FatHMM-W to either tool
score combination (Condel+ or Logit+) led to a performance boost
(Fig. 4; Supp. Figs. S14–S18). However, this did not hold for mixed
proteins, providing strong evidence for type 2 circularity. For mixed
proteins, we observed a significant drop in performance for both
Logit+ and Condel+ on all datasets but SwissVarSelected (see Supp.
Fig. S19).
Discussion
The wealth of pathogenicity prediction tools proposed in the lit-
erature raises the question whether there are systematic differences
in the quality of their predictions when evaluated on a large num-
ber of variant databases. In an attempt to answer this question,
we performed a comparative evaluation of pathogenicity prediction
tools and demonstrated the existence of two types of circularity
that meaningfully impair comparison of in silico pathogenicity pre-
diction tools. We showed how ignoring these effects could lead to
overly optimistic assessments of tool performance. One severe con-
sequence of this phenomenon is that it may hinder the discovery
of novel disease risk genes, as these tools are widely used to choose
variants for further functional investigation.
In this manuscript, we have described and demonstrated “type
1” and “type 2” circularity. Type 1 circularity occurs because of an
overlap between training and evaluation datasets, possibly resulting
in overfitting [Hastie et al., 2009], meaning that a tool is highly
tailored to a given dataset, but will perform worse on novel vari-
ants. Type 1 circularity is a well-known and studied phenomenon
in machine learning [Hastie et al., 2009] and there are guidelines
on how it can be avoided [Vihinen, 2013]. To avoid type 1 circu-
larity, we built the Selected datasets, in which none of the variants
have previously been seen by any of the tools (with the possible and
unavoidable exception of MT2). This makes them the most appro-
priate datasets on which to draw conclusions regarding the relative
performance of the tools. Figure 1 and Supp. Table S1 suggest that
MT2, PP2, and MASS overfit on their training data and have rather
weak generalization abilities.
Our efforts to understand the outstanding performance of
FatHMM-W on four out of five datasets led to additional in-
sights about type 2 circularity. Our findings about type 2 circu-
larity demonstrate that predicting the pathogenicity of a variant —
based on the pathogenicity of all other known variants in the same
protein — is a statistically successful, but ultimately inappropriate
strategy. It is inappropriate because it will often fail to correctly clas-
sify variants in proteins that contain both pathogenic and neutral
variants. Further, it will often fail to discover pathogenic variants in
unannotated proteins.
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Figure 4. Comparison of the performance of two metapredictors (Logit and Condel) and their component tools, across five datasets. Bar heights
reflect AUC for each tool and tool combination. Logit and Condel are metapredictors combiningMASS, PP2, and SIFT. The “+” versions of Logit and
Condel also include FatHMM-W. While effective in prediction, FATHMM-W (alone and in the Logit+ and Condel+ metapredictors) is optimistically
biased due to type 2 circularity (see Results section). In the “Selected” datasets, Logit provides the best unbiased performance. SIFT has the
lowest performance in the HumVar and ExoVar datasets, but it is also the only predictor that is unbiased in these two datasets.
The apparent success of this strategy is due to the fact that, in
variant databases, it is frequently the case that all the variants of
the same protein are annotated with the same status. Furthermore,
pathogenic-only proteins contain many more labeled variants than
neutral-only proteins. In these databases, pathogenic amino acid
substitutions are heavily concentrated in a few key genes (Fig. 2;
Supp. Figs. S7–S9). These observations regarding the distribution
of variants in our datasets likely result — in part — from research
practices relevant to the way variant databases are populated. Often,
an initial discovery of a pathogenic variant in a gene (for a given
disease) leads to additional discoveries of pathogenic variants in
the same gene, in part because a given gene will be more heavily
investigated once it has been identified as harboring pathogenic
variants.
These properties of variant databases explain why we observe
that pathogenicity can be predicted from the annotation of variants
within the same protein by a MV with excellent accuracies (Fig. 1;
Supp. Table S2). They also explain why FatHMM-W, whose predic-
tive power is driven by the pathogenic-to-neutral ratio of variants in
the sameprotein, performs sowell onVariBenchSelected and predict-
SNPSelected (Fig. 1; Supp. Table S2). This approach, however, will
often fail to correctly classify amino acid substitutions in proteins
that contain both pathogenic andneutral variants (Fig. 3; Supp. Figs.
S11 and S12). This partially explains why FatHMM-W performs
worse on SwissVarSelected than on all other datasets, as it contains
many more variants in the most mixed categories (Fig. 3; Fig. S10).
The same phenomenon also occurs when building metapredictors:
the performance of Logit+ and Condel+ are similarly optimistically
biased because they contain FathHMM-W.
The pervasiveness of circularity makes it difficult to draw defini-
tive conclusions regarding the relative performance of these predic-
tion tools. We do nevertheless observe a reassuring trend for tools
trained for the purpose of predicting pathogenicity to outperform
conservation scores. In addition, the Logit combination of SIFT,
PP2, and MASS is a slightly better predictor of pathogenicity than
any of these tools taken individually. Also, for the mixed proteins
in particular, Condel performs better than, or is on par with, Logit
across the datasets (Supp. Fig. S19).
It is important to note that the drop in performance that we ob-
serve when applying a method to a dataset (that it was not trained
on) could also be due to the different definitions of pathogenic-
ity and neutrality used in the different benchmark datasets (see
Table 2). It should be an important goal of future studies to quantify
this impact. However, as long as circularity exists in a comparative
study, it will mask the effect of these differences in the definition of
pathogenicity: in Figure 1, FatHMM-W seems to provide excellent
prediction results across four different benchmark datasets, irre-
spective of the different definitions of pathogenicity and neutrality.
However, our analysis shows that the true origin of this superior
performance is type 2 circularity and not robustness to different
definitions of pathogenicity and neutrality.
Therefore, a key step in future studies examining this problem
will be to avoid any type of circularity. The existence of these types
of circularity has immediate implications for the further devel-
opment and evaluation of pathogenicity prediction tools: at the
very least, and as recommended previously [Vihinen, 2013], pre-
diction tools should only be compared on benchmarks that do
not overlap with any of the datasets used to train the tool. We
provide such datasets, VariBenchSelected, predictSNPSelected, and
SwissVarSelected (see Supp. Data S1) for this kind of independent
evaluation. All prediction tools should make their training datasets
public, as type 1 circularity cannot be excluded if any portion of a
training dataset is kept private.
A more rigorous strategy would be to retrain all predictors on
the same dataset, in order to truly evaluate the predictors and not
the quality of their training datasets. However, this is only possible
if the raw variant descriptors (variant features) — from which the
tools derive their predictions— are made available. We investigated
all tools presented here and only for PP2 was it straightforward to
obtain these descriptors [Adzhubei et al., 2010].
To address the problem of type 2 circularity, it is imperative
that future studies report prediction accuracy as a function of the
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pathogenic-to-neutral ratio, as in Figure 3. An even better strategy
would be to stratify training and test datasets such that variants
from the same protein only occur in either the training or the
test dataset, completely removing the possibility of classification
within the same protein [Adzhubei et al., 2010]. Furthermore, one
could construct predictors for different classes of variants, defined
by the pathogenic-to-neutral ratio in the proteins, to address the
problem that none of the existing tools achieves constantly good
results across these classes on VariBenchSelected. Both these alter-
native approaches, however, rely critically on the availability of raw
descriptors used by the corresponding tools.
Finally, there is another potential source of circularity to beware of
in the future: The novel variants entered in databases may be anno-
tated using existing pathogenicity prediction tools. These tools will
therefore appear to perform well on “new” data (from later versions
of mutation databases), whereas in fact they will only be recovering
labels that they have themselves provided. We therefore advocate
documentation of the sources of evidence that were used to assign
labels to variants when they are entered into a variant database.
This is akin to standard practice for gene function databases, which
record whether the annotation of a gene with a particular function
was biologically validated and/or computationally predicted.
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